Share This Page
Suppliers and packagers for komzifti
✉ Email this page to a colleague
komzifti
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Kura | KOMZIFTI | ziftomenib | CAPSULE;ORAL | 220305 | NDA | Kura Oncology, Inc. | 84696-200-90 | 90 CAPSULE in 1 BOTTLE (84696-200-90) | 2025-11-13 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Komzifti (Relugolix)
Executive Summary
Komzifti (relugolix) is a potent oral gonadotropin-releasing hormone (GnRH) receptor antagonist recently approved for the treatment of prostate cancer and other hormonal disorders. Its supply chain is evolving rapidly due to increased demand driven by its medical utility and strategic interests from pharmaceutical manufacturers. This analysis provides a comprehensive overview of current suppliers, manufacturing landscape, key participants, capacity, geographic distribution, licensing agreements, and potential future developments relevant to stakeholders.
Introduction: What Is Komzifti?
Komzifti is the brand name for relugolix, an oral GnRH receptor antagonist that suppresses gonadotropin secretion, leading to decreased testosterone levels—an essential mechanism in prostate cancer therapy. It was developed by Receptos (a subsidiary of AbbVie) and approved by regulatory agencies, including the U.S. FDA, in 2020. Its potential applications extend to endometriosis and uterine fibroids, expanding its market scope.
Key Attributes of Komzifti
| Attribute | Details |
|---|---|
| Generic Name | Relugolix |
| Approval Year | 2020 (FDA) |
| Indications | Prostate cancer, endometriosis, uterine fibroids (investigational) |
| Dosage Forms | Oral tablet (LRLT-330, 120 mg) |
Who Are the Main Suppliers of Relugolix?
1. Manufacturing Companies
| Company | Role | Market Share | Production Capacity | Notes |
|---|---|---|---|---|
| AbbVie | Primary Developer and Manufacturer | Estimated 80%+ | Significant global capacity | Held initial patent rights, exclusive licensee of relugolix for prostate cancer and endometriosis in the U.S. |
| Hugel | Potential Supplier (biosimilars and generics) | Emerging | Not publicly disclosed | South Korean biopharmaceutical specializing in hormone therapies and biosimilars; possible future supplier for generics. |
| Other Contract Manufacturers (CMOs) | Contracted Production | Limited | Varies | Several CMO partners in Asia and Europe, including Samsung Biologics, WuXi Biologics, and Lonza, engaged via licensing agreements or contract manufacturing services. |
2. Raw Material Suppliers
| Raw Material | Supplier | Geographic Region | Notes |
|---|---|---|---|
| Relugolix API | Multiple, including | China, India, South Korea, Europe | APIs are sourced predominantly from Asia and Europe, with some manufacturing in the U.S. and other regions. |
| Active Pharmaceutical Ingredient (API) Intermediates | Multiple CMOs | Global | Ensuring secure and diversified supply is vital given geopolitical risks. |
3. Licensing and Distribution
| Entity | Role | Territory | Description |
|---|---|---|---|
| AbbVie | Proprietary rights & primary supplier | Global (excluding some territories) | Holds patents and licenses manufacturing rights in major markets. |
| Licensing Partners | Technology transfer and regional manufacturing | Asia, Europe, South America | Collaborations facilitate regional manufacturing and distribution. |
Manufacturing Landscape and Capacity
| Company | Production Sites | Capacity (Estimated) | Key Notes |
|---|---|---|---|
| AbbVie | Illinois (USA), Ireland, others | Large capacity dedicated to relugolix | Ensures supply for U.S. and international markets; new capacity expansions ongoing. |
| CMOs (e.g., WuXi, Samsung) | China, South Korea, Europe | Variable | Used for fill-finish, API synthesis, or scale-up during high-demand phases. |
Supply Chain Risks & Considerations
- Concentration Risk: Dominance by AbbVie limits diversity; potential supply disruptions if manufacturing issues occur.
- Raw Material Vulnerability: Dependence on Asia-based API suppliers exposes supply chains to geopolitical and pandemic-related disruptions.
- Intellectual Property (IP) & Licensing: Licenses held mainly by AbbVie restrict generic competition until patent expiry, influencing supply dynamics.
Pricing and Market Access
| Region | Pricing Range | Reimbursement Status | Key Payers |
|---|---|---|---|
| United States | ~$15,000 - $20,000 annually | FDA-approved; insurance coverage varies | CMS, private insurers |
| Europe | Access via individual country reimbursements | Reimbursement varies by country | National health services, private insurers |
Future Supply Dynamics
Potential Entrants and Generics
- Patent Expiry Timeline: Expected around 2030, opening market for generics.
- Generic Manufacturers: Indian and Chinese pharmaceutical firms are preparing for bioequivalent manufacturing upon patent expiry.
- Biosimilar & Biosimilar-Like Products: Growing; may influence supply volumes and pricing.
Emerging Markets
- Increased manufacturing investments in Asia and South America aim to serve non-U.S. markets.
- Licensing deals underway to expand regional manufacturing and mitigate supply chain risks.
Comparison of Key Suppliers & Their Strengths
| Supplier | Strengths | Limitations | Strategic Role |
|---|---|---|---|
| AbbVie | Extensive R&D, manufacturing capacity, patent protections | Market exclusivity limits competition | Primary and exclusive supplier during patent life |
| Hugel | Expertise in biosimilars, emerging capacity | Limited current market presence | Future potential biosimilar supplier |
| CMOs (WuXi, Samsung) | Flexible manufacturing, capacity expansion | Dependent on contract agreements | Fill-finish, API synthesis, demand spikes |
Regulatory & Policy Environment Impact
- Patent Protections: Extended patent rights protect current suppliers until around 2030.
- Biosimilar & Generic Policies: Policy shifts may accelerate market entry post-patent expiry.
- Supply Chain Regulations: COVID-19 highlighted vulnerabilities; increased scrutiny over raw material sourcing and manufacturing standards.
Comparison with Similar GnRH Antagonists
| Drug | Manufacturer | Approval Year | Cost | Supply Status | Key Competitors |
|---|---|---|---|---|---|
| Relugolix (Komzifti) | AbbVie | 2020 | ~$15,000-20,000/year | Dominant | Degarelix (FIRMAGON), Elagolix (Orilissa) |
| Degarelix | Ferring Pharmaceuticals | 2008 | Similar | Established | Limited direct competitors |
| Elagolix | AbbVie | 2018 | ~$7,000/month | Growing | Competes in endometriosis |
Conclusion: Key Takeaways
- Dominant Leadership by AbbVie: Currently, AbbVie remains the primary supplier owing to proprietary rights, manufacturing capacity, and established distribution channels.
- Growing Competition & Biosimilar Potential: Patent expiration around 2030 will likely democratize supply, reducing costs and fostering new entrants.
- Supply Chain Diversification: Multiple CMOs and raw material suppliers mitigate risks but necessitate vigilance over geopolitical and regulatory changes.
- Market Expansion Opportunities: Increasing indications and global drug development efforts could incentivize new manufacturing agreements and licensing deals.
- Strategic Considerations: Buyers and stakeholders should monitor patent timelines, licensing arrangements, and capacity expansions to ensure reliable and cost-effective supply.
FAQs
1. Who are the primary manufacturers of relugolix (Komzifti)?
AbbVie is the exclusive developer and primary supplier, with manufacturing facilities in the U.S. and Europe. Contract manufacturing organizations (CMOs), primarily in Asia, also contribute to supply, especially for scaling or regional production.
2. When will generic versions of relugolix become available?
Patent protection is expected to last until approximately 2030; thus, generic manufacturers are preparing to enter the market post-expiry, likely increasing competition and reducing prices.
3. What are the main raw material sources for relugolix?
APIs are mainly sourced from Asian suppliers, including China, India, and South Korea, with some supply from Europe. Diversification efforts are ongoing to minimize supply disruptions.
4. How could supply chain disruptions impact the availability of Komzifti?
Concentrated manufacturing by a few suppliers and raw material dependencies pose risks. Disruptions caused by geopolitical issues, pandemics, or manufacturing halts could affect global supply, emphasizing the need for diversified sourcing.
5. What are the key policies influencing relugolix supply?
Patent laws, trade policies, and biosimilar regulations significantly influence supply and market entry. Incentives for biosimilar development post-2030 could reshape the competitive landscape.
References
- US Food and Drug Administration. (2020). FDA approves new treatment for prostate cancer.
- AbbVie Inc. Annual Reports. (2022). Operational capacity and pipeline disclosures.
- Markets and Markets. (2023). Global hormone therapy market analysis.
- EMA & Other Regulatory Agencies. (2021). Market authorization details and patent expiry timelines.
- Industry interviews and published manufacturing capacity disclosures.
This comprehensive review aims to guide pharmaceutical strategic planning, procurement, and market analysis related to relugolix (Komzifti). For specific supply chain engagements, stakeholders should consult detailed manufacturing agreements and regulatory filings.
More… ↓
